SCHEMBL16064965

SCHEMBL16064965

CC(C)(C)CCNC(=O)C12CC3CC(CC(C3)C1)C2

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.60
KDM4E B2RXH2 1/20 0.60
KMT2A Q03164 3/20 0.50
MEN1 O00255 2/20 0.50
EPHX2 P34913 1/20 0.48
LMNA P02545 3/20 0.47
HSD11B1 P28845 2/20 0.47
HPGD P15428 1/20 0.46
POLB P06746 1/20 0.46
ALDH1A1 P00352 3/20 0.45
GLA P06280 1/20 0.45
ITGB1 P05556 1/20 0.45
ITGA4 P13612 1/20 0.45
CYP17A1 P05093 1/20 0.44
CYP19A1 P11511 1/20 0.44
CACNA1H O95180 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17755397 0.90 HTT (0.57) HTTKDM4EKMT2AMEN1EPHX2
SCHEMBL18433968 0.83 KDM4E (0.41) HTTKDM4EKMT2AMEN1EPHX2
SCHEMBL16064957 0.82 HTT (0.54) HTTKDM4EKMT2AMEN1LMNA
SCHEMBL28334704 0.78 KDM4E (0.68) HTTKDM4EKMT2AMEN1EPHX2
SCHEMBL18433716 0.77 KDM4E (0.38) HTTKDM4EKMT2AMEN1EPHX2
SCHEMBL17702625 0.77 KMT2A (0.70) HTTKDM4EKMT2AMEN1EPHX2
SCHEMBL8655345 0.77 KDM4E (0.66) HTTKDM4EKMT2AMEN1EPHX2
SCHEMBL13873443 0.77 HTT (0.66) HTTKDM4EKMT2AMEN1EPHX2
SCHEMBL22005490 0.76 KDM4E (0.60) HTTKDM4EKMT2AMEN1EPHX2
SCHEMBL6891227 0.76 ALDH1A1 (0.62) HTTKDM4EKMT2AMEN1EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9883997-B2 Cosmetic compositions with tricyclodecane amides CONOPCO, INC. (US) 2018-02-06 US disclosed
US-9840466-B2 Process of making adamantanamides CONOPCO, INC. (US) 2017-12-12 US disclosed
EP-2969026-B1 COSMETIC COMPOSITIONS WITH TRICYCLODECANE AMIDES UNILEVER PLC (GB) 2017-11-01 EP disclosed
US-9775793-B2 Prolonged delivery of certain fragrance components from personal care compositions CONOPCO, INC. (US) 2017-10-03 US disclosed
EP-3080086-B1 PROCESS OF MAKING ADAMANTANAMIDES UNILEVER PLC A COMPANY REGISTERED IN ENGLAND AND WALES UNDER COMPANY NO 41424 OF (GB) 2017-07-05 EP disclosed
US-9682028-B2 Personal care photoprotective compositions with tricyclodecane amides CONOPCO, INC. (US) 2017-06-20 US disclosed
US-20170029375-A1 PROCESS OF MAKING ADAMANTANAMIDES CONOPCO, INC., D/B/A UNILEVER (US) 2017-02-02 US disclosed
EP-2968082-B1 PROLONGED DELIVERY OF CERTAIN FRAGRANCE COMPONENTS FROM PERSONAL CARE COMPOSITIONS UNILEVER PLC (GB) 2017-02-01 EP disclosed
US-20160045419-A1 PERSONAL CARE PHOTOPROTECTIVE COMPOSITIONS WITH TRICYCLODECANE AMIDES CONOPCO, INC., D/B/A UNILEVER (US) 2016-02-18 US disclosed
US-20160015616-A1 PROLONGED DELIVERY OF CERTAIN FRAGRANCE COMPONENTS FROM PERSONAL CARE COMPOSITIONS CONOPCO, INC., D/B/A UNILEVER (US) 2016-01-21 US disclosed
US-20160008249-A1 COSMETIC COMPOSITIONS WITH TRICYCLODECANE AMIDES CONOPCO, INC., D/B/A UNILEVER (US) 2016-01-14 US disclosed
WO-2015086428-A1 PROCESS OF MAKING ADAMANTANAMIDES UNILEVER PLC (GB) 2015-06-18 WO disclosed
WO-2014139952-A2 PROLONGED DELIVERY OF CERTAIN FRAGRANCE COMPONENTS FROM PERSONAL CARE COMPOSITIONS UNILEVER PLC (GB) 2014-09-18 WO disclosed
WO-2014139965-A1 PHOTOPROTECTIVE COMPOSITIONS WITH TRICYCLODECANE AMIDES UNILEVER PLC (GB) 2014-09-18 WO disclosed
WO-2014139963-A1 COSMETIC COMPOSITIONS WITH TRICYCLODECANE AMIDES UNILEVER PLC (GB) 2014-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160015616-A1 PROLONGED DELIVERY OF CERTAIN FRAGRANCE COMPONENTS FROM PERSONAL CARE COMPOSITIONS DPM1, DHCR24, POLR1C HTT 2174/4885KDM4E 3863/4885KMT2A 3691/4885
US-20160045419-A1 PERSONAL CARE PHOTOPROTECTIVE COMPOSITIONS WITH TRICYCLODECANE AMIDES CUTA, ERCC1, ERCC5 HTT 101/4885KDM4E 1411/4885KMT2A 2497/4885
US-20160008249-A1 COSMETIC COMPOSITIONS WITH TRICYCLODECANE AMIDES CUTA, ACMSD, LAGE3 HTT 1219/4885KDM4E 569/4885KMT2A 621/4885
US-20170029375-A1 PROCESS OF MAKING ADAMANTANAMIDES APOBEC3G, APOBEC3A, APOBEC3B HTT 1041/4885KDM4E 4025/4885KMT2A 4356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.